News

We are pleased to announce that F1 Pharma S.A. is a silver sponsor and a participant of international conference INTERDISCIPLINARY CONFERENCE ON DRUG SCIENCES ACCORD 2022 „Synergy of...

On 30 October 2019 the Chief Pharmaceutical Inspectorate granted a new Manufacturing Authorisation for F1 Pharma S.A.
As a result of the transformation of F1 Pharma into a joint stock company, we submitted a request to the Chief Pharmaceutical Inspectorate for the amendment of our Manufacturing Authorisation.

F1 Pharma successfully completed project granted by the National Center of Research and Development in Fast Track programme fulfilling both scientific and financial targets.
We are happy to inform that the project of “The development of innovative forms of mucolytic drugs, suitable for application to children, elderly persons and persons suffering from esophageal dysphagia”, funded by the National Centre for Research and Development (NCBiR), under the R&D Business Projects scheme, has been completed, accepted and financially concluded with the NCBiR.

On 6 August 2019 the District Court listed F1 Pharma S.A. in the National Court Register of companies under the KRS number: 0000797961.
F1 Pharma S.A. was conceived as a result of the transformation of F1 Pharma Sp. z o. o. pursuant to the resolution of the Shareholders Meeting based in Kraków, on 3 April 2019, on the transformation of F1 Pharma Sp. z o. o. into a joint stock company.

25th conference of the European Association of Faculties of Pharmacy under the theme „Creative education: towards competences in a patient-oriented pharmacy education” was held between 15 and 17 May 2019. The conference was organized by a team of employees of the Chair of Pharmaceutical Technology and Biopharmacetics of the Medical College of the Jagiellonian University, under the leadership of prof. Renata Jachowicz, Ph.D., with the cooperation of the Conference Organization Department of the Jagiellonian University.  

F1 Pharma receives further financial support for new R&D project from regional funds. Recently we received information on the positive recommendation of the Małopolska Centre for Entrepreneurship regarding our application for the subsidization of our new R&D project entitled “The development of innovative forms of oral drugs dedicated for children and elderly persons suffering from dysphagia”.

F1 Pharma receives funding for the project in the Fast Track programme intended for Small, Middle Enterprises (SMEs), small projects
On 1 December 2017 the Management of F1 Pharma sp. z o.o. has signed a contract agreement with the National Centre for Research and Development (NCBiR) for the subsidization of the project entitled “The development of innovative forms of mucolytic drugs, suitable for application to children, elderly persons and persons suffering from esophageal dysphagia”

F1 Pharma as a Partner of the Jagiellonian University Pharmaceutical Department Dean's Trophy Run On the 17thof October 2015, the first edition of the Pharmaceutical Department Dean's Trophy Run...

Between 13-15 of October 2015, representatives of F1 Pharma participated in the CPhl Worldwide Exhibition in Madrid. The CPhl Worldwide Exhibition is the largest exhibition of the pharmaceutical...

On the 25 th of September this year, the Life Science Park witnessed this year's edition of the Małopolska Night of Scientists. On that exceptional night, organised under the theme of 'Once Upon a...